 |
|
|
| |
Longitudinal Associations of Semaglutide with Liver Fibrosis Score in People with HIV
|
| |
| |
CROI 2026 Feb 22-25 Denver
Osteoporosis, gout could be the latest GLP-1 side effects
Overall, researchers found that roughly 4% of patients taking GLP-1s developed osteoporosis compared to a little over 3% of those not taking GLP-1s. This represented a 30% increased risk of osteoporosis among patients taking GLP-1s. Patients taking GLP-1s also developed osteomalacia - a related condition where bones soften - twice as often as those not on the medications.
GLP-1 users also had slightly higher rates of gout compared to non-users (7.4% versus 6.6%, respectively). The increased risk of gout among patients taking GLP-1s was 12%.
https://www.advisory.com/daily-briefing/2026/03/04/glp-1-side-effects
GLP at CROI
GLP-1 Receptor Agonists: Are They a Cure for Everything? - Todd Brown Review (03/10/26)
Initiating Semaglutide Therapy Reduces Tobacco Cigarette use among People with HIV - (03/07/26)
Tirzepatide use in People with HIV Shows Effectiveness for Weight Loss and Diabetic Control - (03/07/26)
Real-World Outcomes of Tirzepatide Use in People With HIV With and Without Diabetes - (03/07/26)
Evaluation of GLP-1 Medications in an Observational Cohort of People with HIV in Washington, DC (2011-2025) - (03/07/26)
Effects of Semaglutide on Subclinical Cardiovascular Health in People With HIV - (03/07/26)
The Impact of Semaglutide on Depressive Symptoms Among People With HIV - (02/27/26)
Jimmy Ma1, Stephanie A. Ruderman1, Lara Haidar2, Joseph A Delaney1, H. Nina Kim1, Diana Alba3, Sonya Heath4, Y. Joseph Hwang5, Maile Karris6, April C. Pettit7, Allan Rodriguez8,
Bridget M. Whitney1, George A Yendewa9, Heidi M Crane1 for the CFAR Network of Integrated Clinical Systems group
|
| |
|
|
|
|
|
